Literature DB >> 12879985

Bile duct disorders.

André P Geubel1, Christine Sempoux, Jacques Rahier.   

Abstract

Drug-induced bile duct injury related prolonged or chronic cholestasis is recognized as a common side effect of treatment with several drugs. The severity and duration of the clinical symptoms suggest that this increase in number of reports is not only related to clinician and pathologists being increasingly aware of the condition, but also may represent a true increase in incidence likely related to a time-related growing experience with newer drugs. This clinical presentation encompasses a wide variety of features that may be the source of diagnostic difficulties, especially in the cases where cholestasis occurs days or weeks after the completion of therapy. Even more puzzling is the initial picture of hepatocholangitis, which may be silent and ensuing bile duct paucity with chronic anicteric cholestasis may be another source of diagnostic difficulties in the long-term. These diagnostic difficulties suggest that some of the cases of the so-called "idiopathic adulthood ductopenia" may originate from overlooked drug induced vanishing bile duct syndrome. The pathogenesis of the syndrome remains largely unknown and the determinants of prognosis and outcome. From reproducible data obtained in different studies investigating HLA-dependent predisposition, one may assume that genetics plays a major role even if other unknown additive factors are also likely involved. Severity of initial hepatocholangitis is likely to represent another important determinant of severity and prognosis, however to be assessed in larger longitudinal studies. Therapy of large bile duct injury mimics that of primary sclerosing cholangitis. Treatment of small bile duct injury remains disappointing. Corticosteroids are invariably ineffective. Ursodeoxycholic acid as been shown to induce improvement of clinical and biochemical cholestasis in some selected cases, its efficacy being however unpredictable. Preliminary data about the natural history of the vanishing bile duct syndrome suggest that therapy might be more effective when initiated early.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879985     DOI: 10.1016/s1089-3261(03)00028-x

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  4 in total

1.  Vanishing bile duct syndrome and inflammatory pseudotumor associated with a case of anabolic steroid abuse.

Authors:  Franco Capra; Nicoletta Nicolini; Giovanni Morana; Alfredo Guglielmi; Paola Capelli; Italo Vantini
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

Review 2.  Drug-induced cholestasis.

Authors:  Manmeet S Padda; Mayra Sanchez; Abbasi J Akhtar; James L Boyer
Journal:  Hepatology       Date:  2011-04       Impact factor: 17.425

Review 3.  An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters.

Authors:  Kyunghee Yang; Kathleen Köck; Alexander Sedykh; Alexander Tropsha; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2013-05-07       Impact factor: 3.534

4.  Chemotherapy-induced sclerosing cholangitis as a rare indication for resection: report of a case.

Authors:  Yutaro Kato; Kentaro Matsubara; Yoshinobu Akiyama; Hiroaki Hattori; Akira Hirata; Fumio Suzuki; Hitoshi Ohtaka; Ayu Kato; Yoshiaki Sugiura; Masaki Kitajima
Journal:  Surg Today       Date:  2009-09-27       Impact factor: 2.549

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.